| Literature DB >> 35214752 |
Laura Di Renzo1, Laura Franza2, Diego Monsignore1, Ernesto Esposito3, Pierluigi Rio4, Antonio Gasbarrini4, Giovanni Gambassi4, Rossella Cianci4, Antonino De Lorenzo1.
Abstract
Vaccines are among the most effective health measures and have contributed to eradicating some diseases. Despite being very effective, response rates are low in some individuals. Different factors have been proposed to explain why some people are not as responsive as others, but what appears to be of critical importance is the presence of a healthy functioning immune system. In this respect, a key factor in modulating the immune system, both in its adaptive and innate components, is the microbiota. While microbiota can be modulated in different ways (i.e., antibiotics, probiotics, prebiotics), an effective and somewhat obvious mechanism is via nutrition. The science of nutrients and their therapeutic application is called immunonutrition, and it is increasingly being considered in several conditions. Our review will focus on the importance of nutrition and microbiota modulation in promoting a healthy immune system while also discussing the overall impact on vaccination response.Entities:
Keywords: antioxidant system; immunonutrition; inflammation; microbiota; vaccines
Year: 2022 PMID: 35214752 PMCID: PMC8874781 DOI: 10.3390/vaccines10020294
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Figure 1Immune response in eubiosis condition and in immuno-nutrition. Gut homeostasis is maintained through the cooperation between microbiota and several micronutrients, acting in a synergic and powerful way. Eubiosis is maintained by the specific immuno-nutrition (e.g., Vitamin E, Vitamin D, Vitamin C, Omega-3 Fatty acid as EPA and DHA, Se, Zn, Cu and Nucleotides). On the other hand, gut microbiota in eubiosis condition can cooperate with the immune system to preserve the intestinal barrier integrity. Mucosal APCs and associated lymphoid tissue can promote vaccine response, through antigen response and binding Tregs and B lymphocytes via IL-1 and IFN-α. Tregs, activated also through Vitamin E and D, can block Th17 lymphocytes and the related cytokines storm (i.e., IL-17) and suppress inflammation. At the same time, nucleotides, Se and Vitamin C can stimulate B cells to become plasma cells, and produce antigen-specific antibodies. Inside the B cell, the main intracellular signalling pathway promoted by NF-kB pathway related to inflammation is blocked via RXR/PPAR-γ heterodimer. The intracellular defence system, sustained by ROS, is balanced through SOD1 and GPx activity (with binding of Cu, Zn and Se, respectively). EPA and DHA can prevent the lipid bilayer oxidation in cooperation with Vitamin E. Vitamin D and can promote with RXR the anti-oxidant and anti-inflammation gene expression through the binding on VDREs. Abbreviation: Eicosapentaenoic acid (EPA); Docosahexaenoic acid (DHA); Selenium (Se); Zinc (Zn); Copper (Cu); Antigen presenting macrophages/dendritic cells (APCs); Interleukine-1 (IL-1); interferon alpha (IFN-α); Interleukine-17 (IL-17); Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB); Retinoid X receptor (RXR); Peroxisome proliferator-activated receptor (PPAR-γ); Superoxide dismutase 1 (SOD-1); Glutathione Peroxidase (GPx); Vitamin D Responsive Elements (VDREs).
Microbiota composition and response to vaccination.
| Author | Setting | Number of Subjects | Type of Vaccine | Outcome Measure | Reference |
|---|---|---|---|---|---|
| Huda et al., 2019 | Infants | 291 | Bacillus Calmette-Guérin, oral polio virus, tetanus toxoid, hepatitis B virus | [ | |
| Eloe-Fadrosh et al., 2013 | Infants | 17 | Oral live-attenuated typhoid vaccine Ty21a | Cell-mediated immune response was associated with more diverse and complex gut microbiota populations. | [ |
| Kim et al., 2022 | Infants | 122 | Oral Rotavirus Vaccine | Association of Streptococcus and Enterobacteriaceae with seroconversion | [ |
| Parker et al., 2021 | Infants | 486 | Oral Rotavirus Vaccine | Negative correlation between microbiota | [ |
| Harris et al., 2018 | Infants | 30 | Oral Rotavirus Vaccine | Association between vaccine response and higher abundance of | [ |
| Robertson et al., 2021 | Infants | 158 | Oral Rotavirus Vaccine | No association observed with the microbiota composition | [ |
| Borey et al., 2021 | Pigs | 98 | Influenza A virus | Positive immune response is associated with | [ |
| Hagan et al., 2019 | Adults | 22 | Seasonal influenza vaccination | Association between impairment of immune response after antibiotics treatment | [ |
| Nothaft et al., 2021 | Chicken | 60 | Glycoconjugate vaccination against | Involvement of | [ |
| Chac et al., 2021 | Adults | 69 | Oral cholera vaccine | Positive association with an abundance of Clostridiales. Enterobacterales | [ |
| Goncalves et al., 2021 | Adults | 10 | MVA-HIV clade B vaccine | Abundance of Eubacterium in stool and Prevotella in the skin was associated with a positive immune response | [ |
Relevant studies on prebiotics/probiotics supplementation and response to vaccination.
| Reference | Setting | Number of Subjects | Intervention | Duration | Type of Vaccine | Outcome Measure | Reference |
|---|---|---|---|---|---|---|---|
| Van Puyenboreck et al. | Human Clinical trial | 737 |
| 3 weeks | H1N1: Solomon Islands | Univariate and multivariate modelling showed no effect of the probiotic on clinical outcome parameters. | [ |
| Rizzardini et al. | Human Clinical trial | 211 | BB-12® and | 6 weeks | H1N1: Brisbane/59/2007 | Improved immune function by augmenting systemic and mucosal immune responses to challenge. | [ |
| Enani et al. | Human Clinical trial | 112 | 8 weeks | H1N1: California/7/2009 | Improved IgA memory, IgG memory and total IgG in young subjects, but in elderly no significant changes were evaluated. | [ | |
| Langkamp-Henken et al. | Human Clinical trial | 157 | Antioxidants, B vitamins, selenium, zinc, FOS | 10 weeks | H1N1: Caledonia/20/99 | Lymphocyte proliferation to influenza vaccine components was greater in the treated than the control group. | [ |
| Bunout et al. | Human Clinical trial | 66 | FOS | 28 weeks | PPSV 23 | Antibodies against influenza A did not increase. | [ |
| Lomax et al. | Human Clinical trial | 49 | 50:50 mixture of long-chain inulin and FOS | 8 weeks | H1N1: Brisbane/59/2007 | Supplementation can enhance some aspects of the immune response in healthy middle-aged adults, but that is not a global effect. | [ |
| Boge et al. | Human Clinical trial | 222 |
| 13 weeks | H1N1: New | The influenza-specific antibodies in the treated group were increased after vaccination rather than the placebo group. | [ |
| Isolauri et al. | Human Clinical trial | 28 |
| 1 week | D x RRV rhesus-human reassortant live oral rotavirus vaccine | Enhanced IgA seronversion for the treated group. | [ |
| Wang et al. | Animal model (pigs) | 34 | 3 weeks | Att-HRV attenuated human rotavirus | Enhanced innate immune response after vaccination in the treated group. | [ | |
| Wen et al. | Animal model (pigs) | 23 |
| 2 weeks | Att-HRV attenuated human rotavirus. | Enhanced immune response through IgA production. | [ |
| Alqazlan et al. | Animal model (chickens) | 84 | 5 weeks | (WIV) vaccine of inactivated virus H9N2 | Increase of efficacy of vaccinations in chickens using Lactobacilli administration. | [ |
Abbreviations: Lactobacillus casei (L. casei); Bifidobacterium lactis, BB-12® (BB-12®); Bifidobacterium longum (B. longum); Galacto-Oligosaccharides (GOS); Fructooligosaccharides (FOS); Immunoglobulin A (IgA); Immunoglobulin G (IgG).